Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Report from Annual General Meeting of Vitrolife AB (publ)


GOTHENBURG, Sweden, April 25, 2024 /PRNewswire/ --

At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

Gothenburg, April 25, 2024
VITROLIFE AB (publ)
The Board

The information was submitted for publication, through the agency of the contact persons set out above, at 25-04-2024 17:20 CET.

Contact: 
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/report-from-annual-general-meeting-of-vitrolife-ab--publ-,c3967068

The following files are available for download:

https://mb.cision.com/Main/1031/3967068/2761483.pdf

Report from Annual General Meeting of Vitrolife AB (publ)

 

SOURCE Vitrolife AB (publ)


These press releases may also interest you

at 02:34
Elbit Systems Ltd.  ("Elbit Systems" or the "Company") announced today that it was awarded an initial contract of approximately $37 million to supply Iron Fist Active Protection Systems (APS) to General Dynamics Ordnance and Tactical Systems...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...

4 mai 2024
OKX, a leading Web3 technology company, has issued updates for May 3, 2024. OKX today announced that its Web3 Wallet is now...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...



News published on and distributed by: